FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Günther Bernhardt

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Concepts & Ideas

Procedures

Drug Screening Assays, Antitumor

Disorders

Co-author Network

Publications

TOP 3
Nikola Pluym; Max Keller; Paul Baumeister; Günther Bernhardt; Armin Buschauer
[(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
Martin Rothenhöfer; Rosmarie Scherübl; Günther Bernhardt; Jörg Heilmann; Armin Buschauer
Qualitative and quantitative analysis of hyaluronan oligosaccharides with high performance thin layer chromatography using reagent-free derivatization on amino-modified silica and electrospray ionization-quadrupole time-of-flight mass spectrometry coupling on normal phase.
Marco Grundmann; Günther Bernhardt; Armin Buschauer; Martin Rothenhöfer; Frank-Michael Matysik
Fast counter-electroosmotic capillary electrophoresis-time-of-flight mass spectrometry of hyaluronan oligosaccharides.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Günther Bernhardt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nikola Pluym; Max Keller; Paul Baumeister; Günther Bernhardt; Armin Buschauer
[(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
ChemMedChem 2013;8(4):587-93.
2012: Martin Rothenhöfer; Rosmarie Scherübl; Günther Bernhardt; Jörg Heilmann; Armin Buschauer
Qualitative and quantitative analysis of hyaluronan oligosaccharides with high performance thin layer chromatography using reagent-free derivatization on amino-modified silica and electrospray ionization-quadrupole time-of-flight mass spectrometry coupling on normal phase.
Journal of chromatography. A 2012;1248():169-77.
2012: Marco Grundmann; Günther Bernhardt; Armin Buschauer; Martin Rothenhöfer; Frank-Michael Matysik
Fast counter-electroosmotic capillary electrophoresis-time-of-flight mass spectrometry of hyaluronan oligosaccharides.
Analytical and bioanalytical chemistry 2012;402(8):2617-23.
2012: Tobias Birnkammer; Irena Brunskole; Günther Bernhardt; Stefan Dove; Sigurd Elz; Nicole Kagermeier; Miroslaw Lopuch; Roland Seifert; Anja Spickenreither; Armin Buschauer
The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H₂ receptor agonists.
Journal of medicinal chemistry 2012;55(3):1147-60.
2012: Martin Memminger; Nathalie Pop; Erwin von Angerer; Günther Bernhardt; Max Keller; Miroslaw Lopuch; Armin Buschauer
The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.
PloS one 2012;7(12):e51032.
2011: Max Keller; Günther Bernhardt; Armin Buschauer
[³H]UR-MK136: a highly potent and selective radioligand for neuropeptide Y Y₁ receptors.
ChemMedChem 2011;6(9):1566-71.
2011: Nikola Pluym; Nathalie Pop; Ralf Ziemek; Günther Bernhardt; Albert Brennauer; Max Keller; Armin Buschauer
Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
ChemMedChem 2011;6(9):1727-38.
2011: Stephan Braun; Günther Bernhardt; Alexander Botzki; Stefan Dove; Sunnhild Salmen; Christian Textor; Armin Buschauer
Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase.
European journal of medicinal chemistry 2011;46(9):4419-29.
2011: Nathalie Pop; Roland Seifert; Günther Bernhardt; Albert Brennauer; Chiara Cabrele; Patrick Igel; Armin Buschauer
Functional reconstitution of human neuropeptide Y (NPY) Y(2) and Y(4) receptors in Sf9 insect cells.
Journal of receptor and signal transduction research 2011;31(4):271-85.
2011: Cristian Ochoa Puentes; Peter Höcherl; Matthias Kühnle; Stefanie Bauer; Kira Bürger; Günther Bernhardt; Armin Buschauer; Burkhard König
Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
Bioorganic & medicinal chemistry letters 2011;21(12):3654-7.
2011: Max Keller; Daniela Erdmann; Nathalie Pop; Nikola Pluym; Shangjun Teng; Günther Bernhardt; Armin Buschauer
Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
Bioorganic & medicinal chemistry 2011;19(9):2859-78.
2010: Stefan Weiss; Max Keller; Günther Bernhardt; Armin Buschauer; Burkhard König
N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity.
Bioorganic & medicinal chemistry 2010;18(17):6292-304.
2010: Prasanta Ghorai; Anja Kraus; Tobias Birnkammer; Roland Geyer; Günther Bernhardt; Stefan Dove; Roland Seifert; Sigurd Elz; Armin Buschauer
Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.
Bioorganic & medicinal chemistry letters 2010;20(10):3173-6.
2009: Max Keller; Shangjun Teng; Günther Bernhardt; Armin Buschauer
Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
ChemMedChem 2009;4(10):1733-45.
2009: Matthias Kühnle; Michael Egger; Christine Müller; Anne Mahringer; Günther Bernhardt; Gert Fricker; Burkhard König; Armin Buschauer
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Journal of medicinal chemistry 2009;52(4):1190-7.
2009: Patrick Igel; David Schnell; Günther Bernhardt; Roland Seifert; Armin Buschauer
Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([(3)H]UR-PI294), a high-affinity histamine H(3) and H(4) receptor radioligand.
ChemMedChem 2009;4(2):225-31.
2009: Anja Kraus; Prasanta Ghorai; Tobias Birnkammer; David Schnell; Sigurd Elz; Roland Seifert; Stefan Dove; Günther Bernhardt; Armin Buschauer
N(G)-acylated aminothiazolylpropylguanidines as potent and selective histamine H(2) receptor agonists.
ChemMedChem 2009;4(2):232-40.
2008: Prasanta Ghorai; Anja Kraus; Max Keller; Carsten Götte; Patrick Igel; Erich Schneider; David Schnell; Günther Bernhardt; Stefan Dove; Manfred Zabel; Sigurd Elz; Roland Seifert; Armin Buschauer
Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
Journal of medicinal chemistry 2008;51(22):7193-204.
2008: Stefan Weiss; Max Keller; Günther Bernhardt; Armin Buschauer; Burkhard König
Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
Bioorganic & medicinal chemistry 2008;16(22):9858-66.
2008: Roger J Kutta; Edith S A Hofinger; Hendrik Preuss; Günther Bernhardt; Bernhard Dick
Blue-light induced interaction of LOV domains from Chlamydomonas reinhardtii.
Chembiochem : a European journal of chemical biology 2008;9(12):1931-8.
2008: Günther Bernhardt; Bernhard Biersack; Susanne Bollwein; Rainer Schobert; Miroslava Zoldakova
Terpene conjugates of diaminedichloridoplatinum(II) complexes: antiproliferative effects in HL-60 leukemia, 518A2 melanoma, and HT-29 colon cancer cells.
Chemistry & biodiversity 2008;5(8):1645-59.
2008: Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
Journal of cancer research and clinical oncology 2008;134(5):597-607.
2008: Edith S A Hofinger; Julia Hoechstetter; Martin Oettl; Günther Bernhardt; Armin Buschauer
Isoenzyme-specific differences in the degradation of hyaluronic acid by mammalian-type hyaluronidases.
Glycoconjugate journal 2008;25(2):101-9.
2007: Erich Schneider; Max Keller; Albert Brennauer; Bianca K Hoefelschweiger; Dietmar Gross; Otto S Wolfbeis; Günther Bernhardt; Armin Buschauer
Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
Chembiochem : a European journal of chemical biology 2007;8(16):1981-8.
2007: Edith S A Hofinger; Günther Bernhardt; Armin Buschauer
Kinetics of Hyal-1 and PH-20 hyaluronidases: comparison of minimal substrates and analysis of the transglycosylation reaction.
Glycobiology 2007;17(9):963-71.
2007: Edith S A Hofinger; Martin Spickenreither; Jan Oschmann; Günther Bernhardt; Rainer Rudolph; Armin Buschauer
Recombinant human hyaluronidase Hyal-1: insect cells versus Escherichia coli as expression system and identification of low molecular weight inhibitors.
Glycobiology 2007;17(4):444-53.
2007: Christine Müller; Dietmar Gross; vasiliki sarli; Michael Gartner; Athanassios Giannis; Günther Bernhardt; Armin Buschauer
Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
Cancer chemotherapy and pharmacology 2007;59(2):157-64.
2007: Ralf Ziemek; Erich Schneider; Anja Kraus; Chiara Cabrele; Annette G Beck-Sickinger; Günther Bernhardt; Armin Buschauer
Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence.
Journal of receptor and signal transduction research 2007;27(4):217-33.
2006: Ralf Ziemek; Albert Brennauer; Erich Schneider; Chiara Cabrele; Annette G Beck-Sickinger; Günther Bernhardt; Armin Buschauer
Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
European journal of pharmacology 2006;551(1-3):10-8.
2006: Martin Spickenreither; Stephan Braun; Günther Bernhardt; Stefan Dove; Armin Buschauer
Novel 6-O-acylated vitamin C derivatives as hyaluronidase inhibitors with selectivity for bacterial lyases.
Bioorganic & medicinal chemistry letters 2006;16(20):5313-6.
2006: Erich Schneider; Matthias Mayer; Ralf Ziemek; Liantao Li; Christoph Hutzler; Günther Bernhardt; Armin Buschauer
A simple and powerful flow cytometric method for the simultaneous determination of multiple parameters at G protein-coupled receptor subtypes.
Chembiochem : a European journal of chemical biology 2006;7(9):1400-9.
2006: Dietmar Gross; Günther Bernhardt; Armin Buschauer
Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity.
Journal of cancer research and clinical oncology 2006;132(9):589-99.
2006: Daniel J Rigden; Alexander Botzki; Masatoshi Nukui; R Brandon Mewbourne; Ejvis Lamani; Stephan Braun; Erwin von Angerer; Günther Bernhardt; Stefan Dove; Armin Buschauer; Mark J Jedrzejas
Design of new benzoxazole-2-thione-derived inhibitors of Streptococcus pneumoniae hyaluronan lyase: structure of a complex with a 2-phenylindole.
Glycobiology 2006;16(8):757-65.
2005: Sunnhild Salmen; Julia Hoechstetter; Christian Käsbauer; Dietrich Paper; Günther Bernhardt; Armin Buschauer
Sulphated oligosaccharides as inhibitors of hyaluronidases from bovine testis, bee venom and Streptococcus agalactiae.
Planta medica 2005;71(8):727-32.
2004: Ulrich Gürtler; Peter Fuchs; Achim Stangelmayer; Günther Bernhardt; Armin Buschauer; Thilo Spruss
Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion.
Archiv der Pharmazie 2004;337(12):672-81.
2004: Christian Lottner; Ruth Knuechel; Günther Bernhardt; Henri Brunner
Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells.
Cancer letters 2004;215(2):167-77.
2004: Alexander Botzki; Daniel J Rigden; Stephan Braun; Masatoshi Nukui; Sunnhild Salmen; Julia Hoechstetter; Günther Bernhardt; Stefan Dove; Mark J Jedrzejas; Armin Buschauer
L-Ascorbic acid 6-hexadecanoate, a potent hyaluronidase inhibitor. X-ray structure and molecular modeling of enzyme-inhibitor complexes.
The Journal of biological chemistry 2004;279(44):45990-7.
2004: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Günther Bernhardt; Thilo Spruss; Karin Beckenlehner; Marion Koch; Rudolf Krauser; Richard Schlemmer; Ronald Gust; Helmut Schönenberger
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Archiv der Pharmazie 2004;337(6):349-59.
2004: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Günther Bernhardt; Thilo Spruss; Karin Beckenlehner; Marion Koch; Rudolf Krauser; Richard Schlemmer; Ronald Gust; Helmut Schönenberger
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Archiv der Pharmazie 2004;337(6):335-48.
2004: Christian Lottner; Ruth Knuechel; Günther Bernhardt; Henri Brunner
Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates.
Cancer letters 2004;203(2):171-80.
2003: Michael Klein; Manfred Zabel; Günther Bernhardt; Burkhard König
Tetrahydroxy 10-membered cyclic enediynes.
The Journal of organic chemistry 2003;68(24):9379-83.
2003: Martin Oettl; Julia Hoechstetter; Iris Asen; Günther Bernhardt; Armin Buschauer
Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from Streptococcus agalactiae in pharmaceutical preparations.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2003;18(3-4):267-77.
2002: Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
The Journal of clinical investigation 2002;110(9):1309-18.
2002: Thomas S Weiss; Günther Bernhardt; Armin Buschauer; Wolfgang E Thasler; Doris Dolgner; Hubert Zirngibl; Karl-Walter Jauch
Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade.
International journal of colorectal disease 2002;17(6):381-7.
2002: W Vogelhuber; Thilo Spruss; Günther Bernhardt; Armin Buschauer; Achim Göpferich
Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts.
International journal of pharmaceutics 2002;238(1-2):111-21.
2002: Christian Lottner; Karl-Christian Bart; Günther Bernhardt; Henri Brunner
Soluble tetraarylporphyrin-platinum conjugates as cytotoxic and phototoxic antitumor agents.
Journal of medicinal chemistry 2002;45(10):2079-89.
2002: Christian Lottner; Karl-Christian Bart; Günther Bernhardt; Henri Brunner
Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity.
Journal of medicinal chemistry 2002;45(10):2064-78.
2002: Günther Bernhardt; Karin Beckenlehner; Thilo Spruss; Richard Schlemmer; Herta Reile; Helmut Schönenberger
Establishment and characterization of new murine breast cancer cell lines.
Archiv der Pharmazie 2002;335(2-3):55-68.
2001: Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Helmut Schönenberger
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
Archiv der Pharmazie 2001;334(10):309-17.
2001: W Vogelhuber; P Rotunno; E Magni; Andrea Gazzaniga; Thilo Spruss; Günther Bernhardt; Armin Buschauer; Achim Göpferich
Programmable biodegradable implants.
Journal of controlled release : official journal of the Controlled Release Society 2001;73(1):75-88.
2001: Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Ronald Gust; Helmut Schönenberger
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.
Archiv der Pharmazie 2001;334(4):125-37.
2000: Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Helmut Schönenberger
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F1 mice.
Archiv der Pharmazie 2000;333(12):404-14.
2000: Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Helmut Schönenberger
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
Archiv der Pharmazie 2000;333(12):397-403.
2000: I Aiglstorfer; I Hendrich; C Moser; Günther Bernhardt; Stefan Dove; Armin Buschauer
Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
Bioorganic & medicinal chemistry letters 2000;10(14):1597-600.
2000: Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Helmut Schönenberger
Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Archiv der Pharmazie 2000;333(2-3):69-71.
2000: C Moser; Günther Bernhardt; J Michel; H Schwarz; Armin Buschauer
Cloning and functional expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells.
Canadian journal of physiology and pharmacology 2000;78(2):134-42.
1999: A Meister; Günther Bernhardt; V Christoffel; Armin Buschauer
Antispasmodic activity of Thymus vulgaris extract on the isolated guinea-pig trachea: discrimination between drug and ethanol effects.
Planta medica 1999;65(6):512-6.
1999: Günther Bernhardt; Marion Koch; Thilo Spruss; Ronald Gust; Rudolf Krauser; Richard Schlemmer; M Hollstein; F Lux; Helmut Schönenberger
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studies.
Archiv der Pharmazie 1999;332(6):195-200.
1999: Richard Schlemmer; Thilo Spruss; Günther Bernhardt; Helmut Schönenberger
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Archiv der Pharmazie 1999;332(2):59-69.
1998: I Aiglstorfer; A Uffrecht; K Gessele; C Moser; A Schuster; S Merz; Barbara Malawska; Günther Bernhardt; Stefan Dove; Armin Buschauer
NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
Regulatory peptides 1998;75-76():9-21.
1998: I Muckenschnabel; Günther Bernhardt; Thilo Spruss; Armin Buschauer
Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy.
Cancer letters 1998;131(1):71-84.
1998: I Muckenschnabel; Günther Bernhardt; Thilo Spruss; Barbara Dietl; Armin Buschauer
Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers.
Cancer letters 1998;131(1):13-20.
1998: Ronald Gust; Beate Schnurr; Rudolf Krauser; Günther Bernhardt; M Koch; B Schmid; E Hummel; Helmut Schönenberger
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
Journal of cancer research and clinical oncology 1998;124(11):585-97.
1997: M Müller; S Knieps; K Gessele; Stefan Dove; Günther Bernhardt; Armin Buschauer
Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted omega-guanidino- and omega-aminoalkanoic acid amides.
Archiv der Pharmazie 1997;330(11):333-42.
1997: T Weiss; Günther Bernhardt; Armin Buschauer; Karl-Walter Jauch; Hubert Zirngibl
High-resolution reversed-phase high-performance liquid chromatography analysis of polyamines and their monoacetyl conjugates by fluorescence detection after derivatization with N-hydroxysuccinimidyl 6-quinolinyl carbamate.
Analytical biochemistry 1997;247(2):294-304.
1996: F Lux; M Hollstein; H Reile; Günther Bernhardt; Helmut Schönenberger
Discrepancy between cytotoxicity, platinum accumulation, and DNA platination in MCF-7 breast cancer cells treated with diaqua (1,2-diphenylethylenediamine) platinum (II) sulfates and cisplatin.
Biological trace element research 1996;53(1-3):113-28.
1996: I Muckenschnabel; Günther Bernhardt; Thilo Spruss; Armin Buschauer
Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice.
Cancer chemotherapy and pharmacology 1996;38(1):88-94.
1995: Ronald Gust; Günther Bernhardt; Thilo Spruss; Rudolf Krauser; M Koch; Helmut Schönenberger; K H Bauer; S Schertl; Z Lu
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
Archiv der Pharmazie 1995;328(9):645-53.
1995: Thilo Spruss; Günther Bernhardt; Helmut Schönenberger; W Schiess
Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma.
Journal of cancer research and clinical oncology 1995;121(4):193-202.
1993: Thilo Spruss; Günther Bernhardt; Helmut Schönenberger; J Engel
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Journal of cancer research and clinical oncology 1993;119(3):142-9.
1992: Günther Bernhardt; R Müller; Ronald Gust; H Reile; C Keller; Thilo Spruss; Helmut Schönenberger
Dichloro-[1-(hydroxyphenyl)-2-phenylethylenediamine]platinum(II) complexes: testing on the human ovarian cancer cell lines NIH: OVCAR3 and SK OV 3.
Archiv der Pharmazie 1992;325(2):93-9.
1992: H Reile; Günther Bernhardt; M Koch; Helmut Schönenberger; M Hollstein; F Lux
Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation.
Cancer chemotherapy and pharmacology 1992;30(2):113-22.
1992: Günther Bernhardt; Ronald Gust; H Reile; H D vom Orde; R Müller; C Keller; Thilo Spruss; Helmut Schönenberger; T Burgemeister; A Mannschreck
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.
Journal of cancer research and clinical oncology 1992;118(3):209-15.
1992: Günther Bernhardt; Ronald Gust; H Reile; H D vom Orde; R Müller; C Keller; Thilo Spruss; Helmut Schönenberger; T Burgemeister; A Mannschreck
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
Journal of cancer research and clinical oncology 1992;118(3):201-8.
1992: K Beckenlehner; S Bannke; Thilo Spruss; Günther Bernhardt; H Schönenberg; W Schiess
Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.
Journal of cancer research and clinical oncology 1992;118(8):591-6.
1992: D Grimm; F Hofstädter; J Bauer; Thilo Spruss; P Steinbach; Günther Bernhardt; R Menze
Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1).
Virchows Archiv. B, Cell pathology including molecular pathology 1992;62(2):97-104.
1992: Günther Bernhardt; H Reile; H Birnböck; Thilo Spruss; Helmut Schönenberger
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
Journal of cancer research and clinical oncology 1992;118(1):35-43.
1991: H Reile; Thilo Spruss; Günther Bernhardt; R Müller; Ronald Gust; Helmut Schönenberger
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemia.
Archiv der Pharmazie 1991;324(7):405-9.
1991: Thilo Spruss; Günther Bernhardt; E Schickaneder; Helmut Schönenberger
Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Journal of cancer research and clinical oncology 1991;117(5):435-43.
1990: H Reile; H Birnböck; Günther Bernhardt; Thilo Spruss; Helmut Schönenberger
Computerized determination of growth kinetic curves and doubling times from cells in microculture.
Analytical biochemistry 1990;187(2):262-7.
1990: H Reile; Thilo Spruss; R Müller; Ronald Gust; Günther Bernhardt; Helmut Schönenberger; J Engel
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
Archiv der Pharmazie 1990;323(5):301-6.
1990: H Reile; R Müller; Ronald Gust; R Laske; W Krischke; Günther Bernhardt; Thilo Spruss; M Jennerwein; J Engel; S Seeber
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell line.
Archiv der Pharmazie 1990;323(3):133-40.
1990: R Müller; Ronald Gust; Günther Bernhardt; C Keller; Helmut Schönenberger; S Seeber; R Osieka; Alan Eastman; M Jennerwein
[DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.
Journal of cancer research and clinical oncology 1990;116(3):237-44.
1990: H D vom Orde; H Reile; R Müller; Ronald Gust; Günther Bernhardt; Thilo Spruss; Helmut Schönenberger; T Burgemeister; A Mannschreck
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
Journal of cancer research and clinical oncology 1990;116(5):434-8.